Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 13/20 | 0.58 |
| ▸ | GRM2 | Q14416 | 7/20 | 0.58 |
| ▸ | CYSLTR2 | Q9NS75 | 7/20 | 0.53 |
| ▸ | CTSD | P07339 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10957555 | 0.89 | CYSLTR1 (0.58) | CYSLTR1GRM2CYSLTR2CTSDLMNA | |
| SCHEMBL10957548 | 0.89 | CYSLTR1 (0.58) | CYSLTR1GRM2CYSLTR2CTSDLMNA | |
| SCHEMBL7958997 | 0.86 | CTSD (0.63) | CYSLTR1GRM2CYSLTR2CTSDMAPT | |
| SCHEMBL10975157 | 0.85 | CYSLTR1 (0.55) | CYSLTR1GRM2CYSLTR2CTSDMAPT | |
| SCHEMBL10727546 | 0.84 | CYSLTR1 (0.60) | CYSLTR1GRM2CYSLTR2CTSDMAPT | |
| SCHEMBL2893372 | 0.84 | CYSLTR1 (0.60) | CYSLTR1GRM2CYSLTR2CTSDMAPT | |
| SCHEMBL4945030 | 0.84 | CYSLTR1 (0.60) | CYSLTR1GRM2CYSLTR2CTSDMAPT | |
| SCHEMBL13452652 | 0.84 | CYSLTR1 (0.55) | CYSLTR1GRM2CYSLTR2CTSDMAPT | |
| SCHEMBL10975153 | 0.84 | CYSLTR1 (0.52) | CYSLTR1GRM2CYSLTR2CTSDPPARG | |
| SCHEMBL9120538 | 0.84 | MAPT (0.67) | CYSLTR1GRM2CYSLTR2CTSDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-11-27 | — | — | US | disclosed |
| EP-1773774-A2 | HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014918-A2 | HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-6251928-B1 | ADMINISTERING BENZYLIDENE RHODANINES WHICH ARE USEFUL AS AGENTS IN TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH BETA-AMYLOID PEPTIDE IN A MAMMAL | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| US-5747517-A | ALZHEIMER'S DISEASE; PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0677517-A1 | Treatment of Alzheimer's disease employing inhibitors of cathepsin D | ELI LILLY AND COMPANY (US) | 1995-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | GRM2, GRM1, GRIK2 | CYSLTR1 303/4885GRM2 1/4885CYSLTR2 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.